On Thursday, Shares of American Express Company (NYSE:AXP), added 1.99% and closed at $70.11 in the last trading session. The last trading range of the stock ranges between $69.05 and $70.40. Aligning with global travel trends, American Express Travel’s FINE HOTELS & RESORTS will expand in 2017, with the introduction of 77 properties in trending and emerging markets, also debuting a new niche collection that reflects the preferences of recently’s family-focused, luxury travelers. The exclusive hotel program – now over 25 years old – has expanded by nearly 50% over the last five years and 11% since 2016. The FINE HOTELS & RESORTS program offers premium Card Members an exclusive suite of complimentary benefits with an average total value of $550* when booked through American Express Travel.
“Every year, we evolve our portfolio of properties based on hotel industry and customer trends and we partner with the best of the best in the industry,” says Allison Beer, Vice President, Planned Partnerships, American Express Travel. “Our lodging programs are comprised of superior hotel options – a roster that’s carefully curated with our Card Members in mind. We examine internal data, conduct independent property evaluations and place great emphasis on the direct feedback we receive from Card Members to further enhance these exclusive programs. Based on all those inputs, we strive to make Fine Hotels and Resorts the best curated program in the industry.”
Meeting the needs of the evolving global traveler, FINE HOTELS & RESORTS will expand to new global markets counting Copenhagen, Cape Cod and Bath and emerging leisure markets such as Sri Lanka, Ecuador and Mongolia.
Endo International plc – Ordinary Shares (NASDAQ:ENDP), jumped 7.37% and closed at $17.48 in the last trading session. The last trading range of the stock ranges between $16.76 and $17.75. The company’s Market capitalization is $3.63 Billion with the total Outstanding Shares of 222.77 million. Endo International plc develops, manufactures, and distributes pharmaceutical products and devices worldwide. Its U.S. Branded Pharmaceuticals segment offers chronic pain administration products, such as BELBUCA, OPANA ER, and Percocet; Lidoderm for opioid analgesics; and Voltaren gel for osteoarthritis pain, in addition to XIAFLEX for treating Peyronies and Dupuytrens contracture diseases. This segment also provides Supprelin LA for central precocious puberty treatment; testosterone replacement therapies, such as Aveed and TESTOPEL, in addition to Fortesta and Testim gels; Frova and Sumavel DosePro for migraine headaches; Valstar, a sterile solution for intravesical instillation of valrubicin; and Vantas for the palliative treatment of prostate cancer. The companys U.S. Generic Pharmaceuticals segment provides tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics, and transdermal patches for pain administration, urology, central nervous system disorders, immunosuppression, oncology, womens health, and cardiovascular disease markets. Its International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas, counting attention deficit hyperactivity disorder, pain, womens health, and oncology; generic, branded generic, and over-the-counter products in the areas of dermatology and anti-infectives; injectables for the treatment of pain, anti-infectives, cardiovascular, and other therapeutics areas; and healthcare services, products, and solutions to hospitals, pharmacies, and practitioners, in addition to for government healthcare programs.